A major goal of our research is to understand the molecular basis for the effects of MSUD on the brain as a means to developing effective therapy.

We have generated a mouse line that has what we call a floxed E1-alpha gene that will allow us to ask very fundamental questions about MSUD and brain pathology in an animal model. The animals that we have generated (floxed E1-alpha) have DNA pieces put into them that are recognized by the enzyme Cre-recombinase. By breeding with what we call a Cre-mouse (a mouse which expresses the Cre-recombinase enzyme), we are able to remove a portion of the E1-alpha gene and produce an animal with a defective E1- alpha gene. Through several breeding cycles, we first produce animals that have the defective gene (deletion) in one chromosome (+/- animal) then breed those to make animals that have the deletion in both chromosomes (-/- animal). This is the knockout or KO (-/-) animal, because this animal does not produce the E1- alpha protein (or produces a defective protein with a large piece missing). Today there are mouse lines that permit us to create a knockout in the entire animal or in specific organs and tissues. Ultimately we want to generate a mouse that does not express E1- alpha only in the brain.

We have generated MSUD E1 knockout animals by breeding mice heterozygous (one chromosome has the deletion and the other one is normal) for the E1-alpha gene deletion in both chromosomes (-/- or KO animal). These animals are classic MSUD and, as found with the E2 total knockout (*KO), the pups die within 1-2 days of birth. We are using these animals to show the localization of the branched-chain alpha-keto complex (BCKDC) in the brains of the mice. The enzyme is located in nerves (neurons) and not in other types of brain cells, but expression is not uniform throughout the brain. Right now we are breeding the neuron-specific Cre mouse to establish the line here, and then we will mate them with our E1 animals (floxed E1). Animal breeding is a time-consuming process. We hope to produce the desired animals in the next couple of months. The phenotype of these animals will show whether altering brain metabolism is sufficient to produce the neurological effects and determine the next course of experiments. Stay tuned for further updates.

We are also collaborating with Dr. Brendan Lee at Baylor on the phenylbutyrate project. Our laboratory will be doing the cell work, measuring leucine metabolism and the effects of phenylbutyrate on MSUD patient lymphoblast cell lines to determine whether we can predict efficacy.

Editor’s Note: Please see Dr. Hutson’s article in the Fall 2007 Newsletter for more information on this project.
Editor’s Note: Please see Dr. Lee’s article on front cover.

Melvin Carruth

This letter is a tribute to my brother Melvin Carruth! We believe he is one of the oldest living African Americans with Maple Syrup Urine Disease.

Read More

NBS-MSUD Connect: Your One-Stop Shop For MSUD Resources

NBS-MSUD Connect was launched as part of the Newborn Screening Connect patient registry (NBS Connect) in 2013 through a partnership between the Department of Human Genetics at Emory University, the Maple Syrup Urine Disease (MSUD) Family Support Group and other key stakeholders.

Read More

Cambrooke Therapeutics

Cambrooke Therapeutics continues to expand its line of delicious and nutritious low protein foods to help improve the lives of individuals with Inborn Errors of Metabolism such as MSUD.

Read More

Updates To Nutrition Management Guidelines

The Nutrition Management Guideline for MSUD was first published in 2014. Since that time, there have been reports of new research and experiences that have prompted updates of the guideline.

Read More

Emory Metabolic Camp 2018 Announcement

Join us June 18-23, 2018 for the 24th Annual Metabolic Camp at Emory University in Atlanta, GA!

Read More

From The Chairman’s Desk

As I sit here reflecting on how much the care and treatment of MSUD has changed over the years, my mind goes back to 1978 when our son Keith was born.

Read More

MSUD Advocacy Report

Medical Nutrition Equity Act

The Medical Nutrition Equity Act (MNEA) would require all private insurance plans (state regulated or self-insured/self-funded) and federal health programs, including Children’s Health Insurance Program, Tricare, Medicaid, Medicare, and Federal Employee Health Benefit Plans, to provide coverage for formula and low-protein foods for all children and adults with MSUD.

Read More

The MSUD Family Support Group Is Excited To Announce Their Participation In The Million Dollar Bike Ride

The MSUD Family Support Group is excited to announce their participation in The Million Dollar Bike Ride

Read More

19th Biennial MSUD Symposium

I can’t believe that almost two years have passed and it is time for another MSUD Symposium! I am especially excited about this conference because I’ve built in extra time for social interaction.

Read More

Change the lives

of MSUD adults and children

Subscribe to our mailing list

Signup To Our Newsletter Signup with your email address to receive news and updates